Changing to Avastin could save NHS £100m a year - Cameron Optometry | Cameron Optometry
Changing to Avastin could save NHS £100m a year

Changing to Avastin could save NHS £100m a year

Posted on 25th November 2014

The drug Avastin has been in the newscalling for its use in the UK in a bid to save millions each year.

eye-care

Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.

It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.


Related Posts

Coronavirus, COVID-19, advice

10th October 2020

This page will have our latest information on the care we can provide during the COVID-19 pandemic. You can also find information on our Facebook page. LATEST UPDATE 3.00pm, Saturday 10 October Re...

Read more

Treating dry eyes

09th October 2020

The huge increase in individuals working from home has resulted in an increase in patients getting in touch to ask for advice on dry eyes. It might be that people are spending more time on their devic...

Read more

Video consultations

01st October 2020

During lockdown we learned a lot and, whilst we are delighted to be able to see patients in the practice again, video call triaging for patients with eye care emergencies was very effective. So, if yo...

Read more

Appointment booking update

28th September 2020

It finally feels like some sort of normality is being restored in the practice. We resumed the provision of routine eye care in early August and are pleased to have begun rescheduling those patients w...

Read more